Tags : 3L+

Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA

Vartika Singh December 19, 2018

Shots: The P-III NALA Trial involves assessing of Neratinib + capecitabine vs Tykerb (lapatinib) + capecitabine in 621 patients in ratio (1:1) with HER2-Positive Metastatic Breast Cancer The P-III NALA Trial demonstrated improvement in […]readmore

Biotech

Bluebird Bio and Celgene Reports Results of bb21217 in P-I

Vartika Singh December 3, 2018

Shots: The P-I CRB-402 study involves assessing of bb21217 as an investigational anti- BCMA CAR T (150 x 106) cell therapy in patients with r/r multiple myeloma The study demonstrated […]readmore

Tags : 3L+

Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA

Bluebird Bio and Celgene Reports Results of bb21217 in P-I

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : 3L+

Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA

Bluebird Bio and Celgene Reports Results of bb21217 in P-I

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company